Surgical Hemostat Market Synopsis

Surgical Hemostat Market Size Was Valued at USD 4.91 Billion in 2023 and is Projected to Reach USD 8.95 Billion by 2032, Growing at a CAGR of 6.9% From 2024-2032.

Absorbable Hemostat is used adjunctively in operating procedures to support the control of capillary, vein, and small arterial outflow when ligation or other conservative methods of regulator are impractical or unproductive. Innovative Hemostat cut to size for use in endoscopic procedures.

• Hemostats are designed to clamp small blood vessels for outflow control. Another use is to hold and save artificial fascia during undermining and debriding injuries. This equipment is excellent for revealing, exploring, and imagining the deep parts of a wound. Two types of hemostats are generally used in wound care. The typical hemostat is suggested. Better work in minor wounds is often best attended by the 5-inch curved mosquito hemostat with finely serrated jaws.
• The hemostatic apparatus exists in different shapes to use in many operating procedures. These hemostats contain Bainbridge Forceps, Adson Forceps, Mosquito Forceps, Crile Forceps, Kelly Forceps, etc. Surgeons choose the best one according to their comfort and surgical needs, Doctor can perform successful operations.
• Novel and family goods are developed to control continuous medical discharge in separate surgical bleeding conditions, and their routine and safety profiles are supported by medical studies in a wide range of surgical procedures. The newly promoted powdered distribution form of products, Powder is designed to help in mild-to-moderate intensity hemorrhage in a range of tissue shells including broad or rare surfaces and locations where contact or placement of fabric ORC products may be stimulating or impractical.

Surgical Hemostat Market Trend Analysis

Increasing the Number of Surgery and Trauma Cases

• Bleeding produced by trauma or surgery is a serious problem for health, and uncontrollable bleeding can result in death. Developing effective, safe, and convenient hemostatic materials is significant. Rapid and active hemostasis can decrease the possibility of the spread of trauma cells with blood. Hemostatic ingredients are the main applications in the field of wound care, and it is also used for hemostasis during malignant trauma surgery.
• Operating care has been a vital factor for health care globally for over a century. Traumatic injuries, cancers, and cardiovascular disease continue to increase, and the impact of operating involvement on the health of the public will always in growing.
• Bleeding is the most feared problem of surgery and a frequent reason for important perioperative injuries. Several red blood cells are used in the operating situation. To transferable problems, transfusion is related to several non-infectious side effects and is attended by extensive costs to the healthcare system. Operating site bleeding leads to transfusion but it can need reoperation and is related to other problems with coagulopathy and hematoma formation. While the surgery is done at the time hemostatic ingredients are used to reduce bleeding.

Increasing Prevalence of Cardiovascular Diseases

• In cardiovascular surgery, a great therapeutic requirement for hemostasis is in operating procedures of the heart and coronary veins. Closing abilities to provide suture support in vascular operations are extremely required. Liquid tight suture holes closing on top of accelerating the hemostatic cascade are standards of a hemostasis and sealant area as a dual-action cover in a variety of cardiovascular signals established by evidence-based medication.
• Hemostasis in cardiac surgery is still a severe problem for physicians. Blood and its products are the most valued at the same time unsafe for surgeons. Companies produce numerous biological or non-biological goods, which raise the price of operations, and are existing for this issue. Decision-making and creating solutions are the most significant goods of a cardiac surgeon.

Surgical Hemostat Market Segment Analysis:

Surgical Hemostat Market is Segmented based on Product Type, application, Formulation, end-users and Region

By Type, Thrombin based segment is expected to dominate the market during the forecast period

In the operating process, hemostasis is vital to achievement. Clinical ligation of bleeding vessels or electrocautery of minor vessels fails or is not possible, therefore doctors trust thrombin. Thrombin has several well-studied biological actions, it helps to realize coagulation and hemostasis, from tissue injury and bleeding, exposed collagen, and released tissue influence causes stimulation of the essential and extrinsic coagulation paths.

Thrombin can be performed directly on several cell types. The smooth muscle cell causes vasoconstriction it aids in hemostasis. Activating platelets encourages their combination at the place of the thrombus. Activated thrombin also turns into a mitogen and chemoattractant for neutrophils and fibroblasts, and uniformly induces the formation of vascular endothelial development effect for tissue and vascular renovation and restoration.

By Formulation, Sponge Hemostats segment held the largest in 2023

The sponge is a therapeutic device intended for application to bleeding sides as a hemostatic. Sponge is water-insoluble, off-white, nonelastic, porous, flexible product made from cleaned porcine skin, Gelatin USP Granules, and Water for Injection, USP. It is able to absorb and hold within its spaces, many times its weight of blood and other fluids. Physical surface modification of a gelatin sponge is caused a quickly absorbable hemostat that establishes greater bond and hemostasis to other advanced hemostats.

Gelatin sponges are cheap to manufacture, contain no bloodderived ingredients, can be safely reabsorbed by the body and are effective hemostats. it is used under the care of a health care professional as a topical dressing for the temporary treatment of moderate to severely bleeding wounds such as surgical wounds (post-operative, donor sites, dermatological), cuts, and lacerations and for the treatment of mild bleeding from topical ENT surgical wounds and nosebleeds. It is also indicated for control of bleeding from the skin at percutaneous needle access, vascular access and percutaneous catheter access sites.

Surgical Hemostat Market Regional Insights:

North America Expected to Dominate the Market Over the Forecast period

The U.S. has thousands of hospitals and health centers across all 50 states. While many of these hospitals specialize in certain types of care, the vast majority perform surgeries of some form every day. For instance, The U.S. hospital that performed the most surgeries in 2023 is Ochsner LSU Health Shreveport - St Mary Medical Center, located in Shreveport, Louisiana. This facility is a leading academic medical center affiliated with Louisiana State University, and it performed an estimated 236,873 surgeries in 2023.

The number of ambulatory operations centers in the US has increased over the past several years. This was partially cancelled by advances in medical technology that made many operations less invasive, allowing them to be performed on an outpatient basis.

Surgical Hemostat Top Key Active Players

• Becton, Dickinson and Company (US)
• Medtronic plc (US)
• Teleflex Corporation (US)
• Baxter International Inc. (US)
• B. Braun Melsungen AG (Germany)
• Stryker Corporation (US)
• CuraMedical BV (Netherlands)    
• Gelita Medical GmbH (Germany)
• Integra LifeSciences (US)
• Marine Polymer Technologies, Inc
• Hemostasis LLC (US)
• Artivion, Inc. (U.S.)
• Biom'up (U.S.)
• Medtronic (Ireland)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Z-Medica LLC (United States)
• Anika Therapeutics Inc. (US)
• Ethicon Inc. (US) and other Active players

Key Industry Developments in the Surgical Hemostat Market:

• In August 2023, the Teleflex Corporation received U.S. FDA clearance for its QuickPort Control+ Hemostatic Device. This device helps surgeons to control bleeding during cardiac surgical procedures. Therefore, approval of this product helped the company to enhance its product offerings.
• In November 2023, Ethicon announced CE mark approval for its adjunctive hemostat solution ETHIZIA. ETHIZIA Hemostatic Sealing Patch is used for disrupting bleeding on internal organs, except neurological and cardiovascular. This helped company to strengthen its product portfolio.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Surgical Hemostat Market by Product Type
 5.1 Surgical Hemostat Market Overview Snapshot and Growth Engine
 5.2 Surgical Hemostat Market Overview
 5.3 Thrombin Based
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Thrombin Based: Geographic Segmentation
 5.4 Oxidized Regenerated Cellulose Based
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Oxidized Regenerated Cellulose Based: Geographic Segmentation
 5.5 Gelatin Based
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Gelatin Based: Geographic Segmentation
 5.6 Collagen Based Hemostat
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Collagen Based Hemostat: Geographic Segmentation
 5.7 Others
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Others: Geographic Segmentation

Chapter 6: Surgical Hemostat Market by Application
 6.1 Surgical Hemostat Market Overview Snapshot and Growth Engine
 6.2 Surgical Hemostat Market Overview
 6.3 Neurological Surgery
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Neurological Surgery: Geographic Segmentation
 6.4 Cardiovascular Surgery
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Cardiovascular Surgery: Geographic Segmentation
 6.5 Reconstructive Surgery
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Reconstructive Surgery: Geographic Segmentation
 6.6 Gynecological Surgery
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Gynecological Surgery: Geographic Segmentation
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Surgical Hemostat Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Surgical Hemostat Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Surgical Hemostat Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 CR BARD INC. (UNITED STATES)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 B. BRAUN MELSUNGEN AG (GERMANY)
 7.4 BAXTER INTERNATIONAL INC. (UNITED STATES)
 7.5 INTEGRA LIFESCIENCES (UNITED STATES)
 7.6 MARINE POLYMER TECHNOLOGIES INC. (UNITED STATES)
 7.7 TELEFLEX (UNITED STATES)
 7.8 ETHICON INC. (UNITED STATES)
 7.9 PFIZER INC. (UNITED STATES)
 7.10 Z-MEDICA LLC (UNITED STATES)
 7.11 GELITA MEDICAL GMBH (GERMANY)
 7.12 ANIKA THERAPEUTICS INC. (UNITED STATES)
 7.13 STRYKER (UNITED STATES)
 7.14 INTEGRA LIFESCIENCES CORPORATION (UNITED STATES)
 7.15 OTHER MAJOR PLAYERS

Chapter 8: Global Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Product Type
  8.2.1 Thrombin Based
  8.2.2 Oxidized Regenerated Cellulose Based
  8.2.3 Gelatin Based
  8.2.4 Collagen Based Hemostat
  8.2.5 Others
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Neurological Surgery
  8.3.2 Cardiovascular Surgery
  8.3.3 Reconstructive Surgery
  8.3.4 Gynecological Surgery
  8.3.5 Others

Chapter 9: North America Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Product Type
  9.4.1 Thrombin Based
  9.4.2 Oxidized Regenerated Cellulose Based
  9.4.3 Gelatin Based
  9.4.4 Collagen Based Hemostat
  9.4.5 Others
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Neurological Surgery
  9.5.2 Cardiovascular Surgery
  9.5.3 Reconstructive Surgery
  9.5.4 Gynecological Surgery
  9.5.5 Others
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Product Type
  10.4.1 Thrombin Based
  10.4.2 Oxidized Regenerated Cellulose Based
  10.4.3 Gelatin Based
  10.4.4 Collagen Based Hemostat
  10.4.5 Others
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Neurological Surgery
  10.5.2 Cardiovascular Surgery
  10.5.3 Reconstructive Surgery
  10.5.4 Gynecological Surgery
  10.5.5 Others
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Product Type
  11.4.1 Thrombin Based
  11.4.2 Oxidized Regenerated Cellulose Based
  11.4.3 Gelatin Based
  11.4.4 Collagen Based Hemostat
  11.4.5 Others
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Neurological Surgery
  11.5.2 Cardiovascular Surgery
  11.5.3 Reconstructive Surgery
  11.5.4 Gynecological Surgery
  11.5.5 Others
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Product Type
  12.4.1 Thrombin Based
  12.4.2 Oxidized Regenerated Cellulose Based
  12.4.3 Gelatin Based
  12.4.4 Collagen Based Hemostat
  12.4.5 Others
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Neurological Surgery
  12.5.2 Cardiovascular Surgery
  12.5.3 Reconstructive Surgery
  12.5.4 Gynecological Surgery
  12.5.5 Others
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Surgical Hemostat Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Product Type
  13.4.1 Thrombin Based
  13.4.2 Oxidized Regenerated Cellulose Based
  13.4.3 Gelatin Based
  13.4.4 Collagen Based Hemostat
  13.4.5 Others
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Neurological Surgery
  13.5.2 Cardiovascular Surgery
  13.5.3 Reconstructive Surgery
  13.5.4 Gynecological Surgery
  13.5.5 Others
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. SURGICAL HEMOSTAT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. SURGICAL HEMOSTAT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. SURGICAL HEMOSTAT MARKET COMPETITIVE RIVALRY
TABLE 005. SURGICAL HEMOSTAT MARKET THREAT OF NEW ENTRANTS
TABLE 006. SURGICAL HEMOSTAT MARKET THREAT OF SUBSTITUTES
TABLE 007. SURGICAL HEMOSTAT MARKET BY PRODUCT TYPE
TABLE 008. THROMBIN BASED MARKET OVERVIEW (2016-2028)
TABLE 009. OXIDIZED REGENERATED CELLULOSE BASED MARKET OVERVIEW (2016-2028)
TABLE 010. GELATIN BASED MARKET OVERVIEW (2016-2028)
TABLE 011. COLLAGEN BASED HEMOSTAT MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. SURGICAL HEMOSTAT MARKET BY APPLICATION
TABLE 014. NEUROLOGICAL SURGERY MARKET OVERVIEW (2016-2028)
TABLE 015. CARDIOVASCULAR SURGERY MARKET OVERVIEW (2016-2028)
TABLE 016. RECONSTRUCTIVE SURGERY MARKET OVERVIEW (2016-2028)
TABLE 017. GYNECOLOGICAL SURGERY MARKET OVERVIEW (2016-2028)
TABLE 018. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 019. NORTH AMERICA SURGICAL HEMOSTAT MARKET, BY PRODUCT TYPE (2016-2028)
TABLE 020. NORTH AMERICA SURGICAL HEMOSTAT MARKET, BY APPLICATION (2016-2028)
TABLE 021. N SURGICAL HEMOSTAT MARKET, BY COUNTRY (2016-2028)
TABLE 022. EUROPE SURGICAL HEMOSTAT MARKET, BY PRODUCT TYPE (2016-2028)
TABLE 023. EUROPE SURGICAL HEMOSTAT MARKET, BY APPLICATION (2016-2028)
TABLE 024. SURGICAL HEMOSTAT MARKET, BY COUNTRY (2016-2028)
TABLE 025. ASIA PACIFIC SURGICAL HEMOSTAT MARKET, BY PRODUCT TYPE (2016-2028)
TABLE 026. ASIA PACIFIC SURGICAL HEMOSTAT MARKET, BY APPLICATION (2016-2028)
TABLE 027. SURGICAL HEMOSTAT MARKET, BY COUNTRY (2016-2028)
TABLE 028. MIDDLE EAST & AFRICA SURGICAL HEMOSTAT MARKET, BY PRODUCT TYPE (2016-2028)
TABLE 029. MIDDLE EAST & AFRICA SURGICAL HEMOSTAT MARKET, BY APPLICATION (2016-2028)
TABLE 030. SURGICAL HEMOSTAT MARKET, BY COUNTRY (2016-2028)
TABLE 031. SOUTH AMERICA SURGICAL HEMOSTAT MARKET, BY PRODUCT TYPE (2016-2028)
TABLE 032. SOUTH AMERICA SURGICAL HEMOSTAT MARKET, BY APPLICATION (2016-2028)
TABLE 033. SURGICAL HEMOSTAT MARKET, BY COUNTRY (2016-2028)
TABLE 034. CR BARD INC. (UNITED STATES): SNAPSHOT
TABLE 035. CR BARD INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 036. CR BARD INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 037. CR BARD INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. B. BRAUN MELSUNGEN AG (GERMANY): SNAPSHOT
TABLE 038. B. BRAUN MELSUNGEN AG (GERMANY): BUSINESS PERFORMANCE
TABLE 039. B. BRAUN MELSUNGEN AG (GERMANY): PRODUCT PORTFOLIO
TABLE 040. B. BRAUN MELSUNGEN AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. BAXTER INTERNATIONAL INC. (UNITED STATES): SNAPSHOT
TABLE 041. BAXTER INTERNATIONAL INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 042. BAXTER INTERNATIONAL INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 043. BAXTER INTERNATIONAL INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. INTEGRA LIFESCIENCES (UNITED STATES): SNAPSHOT
TABLE 044. INTEGRA LIFESCIENCES (UNITED STATES): BUSINESS PERFORMANCE
TABLE 045. INTEGRA LIFESCIENCES (UNITED STATES): PRODUCT PORTFOLIO
TABLE 046. INTEGRA LIFESCIENCES (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. MARINE POLYMER TECHNOLOGIES INC. (UNITED STATES): SNAPSHOT
TABLE 047. MARINE POLYMER TECHNOLOGIES INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 048. MARINE POLYMER TECHNOLOGIES INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 049. MARINE POLYMER TECHNOLOGIES INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. TELEFLEX (UNITED STATES): SNAPSHOT
TABLE 050. TELEFLEX (UNITED STATES): BUSINESS PERFORMANCE
TABLE 051. TELEFLEX (UNITED STATES): PRODUCT PORTFOLIO
TABLE 052. TELEFLEX (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. ETHICON INC. (UNITED STATES): SNAPSHOT
TABLE 053. ETHICON INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 054. ETHICON INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 055. ETHICON INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. PFIZER INC. (UNITED STATES): SNAPSHOT
TABLE 056. PFIZER INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 057. PFIZER INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 058. PFIZER INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. Z-MEDICA LLC (UNITED STATES): SNAPSHOT
TABLE 059. Z-MEDICA LLC (UNITED STATES): BUSINESS PERFORMANCE
TABLE 060. Z-MEDICA LLC (UNITED STATES): PRODUCT PORTFOLIO
TABLE 061. Z-MEDICA LLC (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. GELITA MEDICAL GMBH (GERMANY): SNAPSHOT
TABLE 062. GELITA MEDICAL GMBH (GERMANY): BUSINESS PERFORMANCE
TABLE 063. GELITA MEDICAL GMBH (GERMANY): PRODUCT PORTFOLIO
TABLE 064. GELITA MEDICAL GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. ANIKA THERAPEUTICS INC. (UNITED STATES): SNAPSHOT
TABLE 065. ANIKA THERAPEUTICS INC. (UNITED STATES): BUSINESS PERFORMANCE
TABLE 066. ANIKA THERAPEUTICS INC. (UNITED STATES): PRODUCT PORTFOLIO
TABLE 067. ANIKA THERAPEUTICS INC. (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. STRYKER (UNITED STATES): SNAPSHOT
TABLE 068. STRYKER (UNITED STATES): BUSINESS PERFORMANCE
TABLE 069. STRYKER (UNITED STATES): PRODUCT PORTFOLIO
TABLE 070. STRYKER (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. INTEGRA LIFESCIENCES CORPORATION (UNITED STATES): SNAPSHOT
TABLE 071. INTEGRA LIFESCIENCES CORPORATION (UNITED STATES): BUSINESS PERFORMANCE
TABLE 072. INTEGRA LIFESCIENCES CORPORATION (UNITED STATES): PRODUCT PORTFOLIO
TABLE 073. INTEGRA LIFESCIENCES CORPORATION (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 074. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 075. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 076. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. SURGICAL HEMOSTAT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. SURGICAL HEMOSTAT MARKET OVERVIEW BY PRODUCT TYPE
FIGURE 012. THROMBIN BASED MARKET OVERVIEW (2016-2028)
FIGURE 013. OXIDIZED REGENERATED CELLULOSE BASED MARKET OVERVIEW (2016-2028)
FIGURE 014. GELATIN BASED MARKET OVERVIEW (2016-2028)
FIGURE 015. COLLAGEN BASED HEMOSTAT MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. SURGICAL HEMOSTAT MARKET OVERVIEW BY APPLICATION
FIGURE 018. NEUROLOGICAL SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 019. CARDIOVASCULAR SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 020. RECONSTRUCTIVE SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 021. GYNECOLOGICAL SURGERY MARKET OVERVIEW (2016-2028)
FIGURE 022. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 023. NORTH AMERICA SURGICAL HEMOSTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. EUROPE SURGICAL HEMOSTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. ASIA PACIFIC SURGICAL HEMOSTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. MIDDLE EAST & AFRICA SURGICAL HEMOSTAT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. SOUTH AMERICA SURGICAL HEMOSTAT MARKET OVERVIEW BY COUNTRY (2016-2028)